<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004883</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02318</org_study_id>
    <secondary_id>CLB-39810</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CDR0000067555</secondary_id>
    <nct_id>NCT00004883</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2</brief_title>
  <official_title>A Phase II Trial of Trastuzumab (Herceptin) for Advanced Stage (IIIB, IV), HER2 Overexpressing, Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage&#xD;
      IIIB or stage IV non-small cell lung cancer that overexpresses HER2. Monoclonal antibodies&#xD;
      can locate tumor cells and either kill them or deliver tumor-killing substances to them&#xD;
      without harming normal cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the activity of trastuzumab (Herceptin) in patients with stage IIIB or IV&#xD;
      HER2-overexpressing non-small cell lung cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the duration of response in patients treated with this regimen. II. Determine&#xD;
      the toxicity of this treatment regimen in this patient population.&#xD;
&#xD;
      III. Assess levels of circulating HER2 and correlate with HER2 expression in this patient&#xD;
      population.&#xD;
&#xD;
      V. Correlate circulating HER2 levels with non-small cell lung cancer tissue HER2 expression.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues&#xD;
      once a week in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression or death.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 84 patients (42 per stratum) will be accrued for this study&#xD;
      within 17.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response [CR] and partial response [PR])</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From registration until death or last known follow-up, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used to describe OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>Time between registration and disease progression, death, or last known follow-up, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used to describe FFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time between the initial documentation of response and subsequent failure (death, disease progression), assessed up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used to describe duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI's Common Toxicity Criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The frequency of occurrence of various toxicities will be tabulated by the most severe occurrence experienced by each individual patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between HER2 expression in tumor tissue and serum</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A 95% confidence interval for this proportion will be estimated using the binomial distribution. The level of circulating HER2 receptor will be descriptively summarized with means, medians, quartiles, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (trastuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (trastuzumab)</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (trastuzumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed stage IIIB or IV non-small cell lung cancer&#xD;
&#xD;
               -  Supraclavicular node involvement allowed&#xD;
&#xD;
               -  Malignant pleural effusion allowed (cytological confirmation not required if&#xD;
                  pleural fluid bloody or exudative)&#xD;
&#xD;
          -  No stage IIIB patients eligible for CLB protocols comprising combined chemotherapy and&#xD;
             chest radiotherapy&#xD;
&#xD;
          -  Recurrent disease allowed&#xD;
&#xD;
          -  HER2 overexpression (2-3+)&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are not considered measurable:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  LVEF at least 45% (by echocardiogram or MUGA)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No concurrent immunologic disease (e.g., autoimmune disease)&#xD;
&#xD;
          -  No history of allergy to murine products&#xD;
&#xD;
          -  No prior murine antibodies&#xD;
&#xD;
          -  No prior anthracyclines&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for lung cancer&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent steroids except for adrenal failure or dexamethasone as an antiemetic&#xD;
&#xD;
          -  No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin&#xD;
             for diabetes)&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Clamon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>September 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

